Nathan R. Barefoot

Bevacizumab Reduces Epistaxis‐Related Operative Burden in Hereditary Hemorrhagic Telangiectasia

Key Points Bevacizumab reduced epistaxis‐related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standa...